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The mixed lineage leukemia gene (MLL, also known as
HRX, ALL-1 and Htrx) located at 11q23 is involved in
translocations with over 40 different chromosomal bands
in a variety of leukemia subtypes. Here we report our
analysis of a rare but recurring translocation,
t(11;15)(q23;q14). This translocation has been described
in a small subset of cases with both acute myeloblastic
leukemia and ALL. Recent studies have shown that MLL
is fused to AF15q14 in the t(11;15). Here we analyse a
sample from another patient with this translocation and
confirm the presence of an MLL–AF15q14 fusion.
However, we have also identified and cloned another
fusion transcript from the same patient sample. In this
fusion transcript, MLL is fused to a novel gene, MLL
partner containing FYVE domain (MPFYVE). Both
MLL–AF15q14 andMLL–MPFYVE are in-frame fusion
transcripts with the potential to code for novel fusion
proteins. MPFYVE is also located on chromosome 15,
approximately 170 kb telomeric to AF15q14. MPFYVE
contains a highly conserved motif, the FYVE domain
which, in other proteins, has been shown to bind to
phosphotidyl-inositol-3 phosphate (PtdIns(3)P). The
MLL–MPFYVE fusion may be functionally important
in the leukemia process in at least some patients contain-
ing this translocation.
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Introduction
Chromosomal translocations involving chromosomal
band 11q23 are the single most common cytogenetic
abnormality in infants with acute leukemia, regardless
of the phenotype (Kaneko et al., 1988; Gibbons et al.,
1990; Martinez-Climent et al., 1995; DiMartino and
Cleary, 1999). The mixed lineage leukemia gene (MLL,
also known as HRX, ALL-1 and Htrx) located at 11q23
is involved in translocations with over 40 different
chromosomal bands in a variety of leukemia subtypes
(Rowley, 1999). All translocation breaks in MLL occur
in an 8.3 kb BamHI genomic segment named the
breakpoint cluster region (BCR), encompassing exons
8–14 (numbering according to Nilson et al., 1996;
Thirman et al., 1993).
MLL is a large protein with an estimated molecular
mass of 430 kDa. The amino-terminus of MLL contains
three AT-hook motifs, a transcriptional repression
domain and a region of homology to mammalian
DNA methyltransferase, all of which are retained in
each MLL fusion protein found to date (Gu et al., 1992;
Tkachuk et al., 1992; Zeleznik-Le et al., 1994). The
carboxy-terminal half of the MLL protein contains the
plant homeobox domain (PHD) and the SET domain
(Su(var)3-9, enhancer of zeste and trithorax), which are
highly homologous to similar domains found in the
Drosophila protein, trithorax (trx). The trx protein is a
positive regulator of homeotic genes that are required
for normal embryonic and adult development of
Drosophila (Breen and Harte, 1993). The heterozygous
Mll mutant mice show abnormal expression of some of
the Hox genes, providing further evidence that MLL is
the mammalian homolog of trx (Yu et al., 1995). In
addition, the expression of many Hox genes is not
properly maintained in embryonic fibroblasts derived
from Mll homozygous mutant mice (Hanson et al.,
1999).
The mechanism of action of the MLL fusion proteins
in the development of leukemia is unclear. At present, 30
different partner genes to which MLL is fused by
translocations have been cloned as an initial step to
elucidate the mechanism of leukemogenesis caused by
the 11q23 translocations (Ayton and Cleary, 2001). The
partner proteins do not share any distinct common
sequence motif and are functionally diverse, ranging
from potential nuclear transcription factors to cytoplas-
mic structural proteins.
Present evidence indicates that the fusion proteins
formed by translocations involving the MLL gene
play an important role in leukemogenesis. MLL
translocations always yield in-frame fusion mRNA
where the 50 portion of MLL is fused to different
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partner genes, giving rise to novel fusion genes and
proteins (Rowley, 1993; Thirman et al., 1993; Bernard
and Berger, 1995; Waring and Cleary, 1997). In a
murine bone marrow immortalization system, the MLL
partner genes ENL, ELL and CBP were critical for
immortalization and leukemogenesis (Lavau et al., 1997,
2000a, b). Thus, it is clear that the partner genes
contribute to the leukemogenic ability of the MLL
fusions but their exact role is still not determined. Most
of the common MLL translocations have been cloned.
Studying the rare but recurrent translocations such as
t(11;15) may offer some insight regarding the role of
MLL partner genes.
Here we report on our analysis of a rare but recurring
translocation, t(11;15)(q23;q14), from an 11-year-old
boy with acute myeloblastic leukemia (AML-M2). This
translocation has been described in a small subset of
cases of both AML and ALL (Raimondi et al., 1989;
Hunger et al., 1993; Thirman et al., 1993; Rubnitz et al.,
1994; Hernandez et al., 1995; Hayette et al., 2000).MLL
involvement in this case was confirmed previously by
Southern hybridization (Thirman et al., 1993). Recent
studies have shown that MLL is fused to AF15q14 in
t(11;15)(q23;q14) (Hayette et al., 2000). Here, we
confirm the presence of the MLL–AF15q14 fusion in
our patient sample. In addition to the MLL–AF15q14
fusion transcript, we have cloned another fusion
transcript from the same patient sample in which
MLL is fused to a novel gene, MLL partner containing
FYVE domain (MPFYVE).
Results
An 11-year-old boy with de novo AML-M2 had a
complex karyotype of 46,XY(18 cells)/47,XY, del(4)
(q2?3q2?8),dic(6;17)(q27;p11),del(7)(p13p21), 15,t(11;15)
(q23;q14),t(12;12)(q13;q23),+mar1, +mar2, +mar3(3
cells)/NCA: similar to clone 1, 9,18, 21, dic(6;17)
(1 cell). MLL involvement in the t(11;15)(q23;q14) was
shown by a Southern blot analysis using genomic DNA
from the bone marrow cells collected at the time of
relapse (Thirman et al., 1993).
At the time of initiation of this study, cloning
of the MLL partner gene AF15q14 was reported in an
abstract (Kuefer et al., 1997). We received partial
sequence information of AF15q14 from Dr Steve Morris
(St Jude Hospital, TN, USA). After performing nested
PCR with the MLL top primer, MLL 5NP, and an
AF15q14 bottom primer, AF15 NP2, a distinct 400 bp
amplified product was obtained (data not shown).
Sequencing this product revealed that the MLL exon
8 sequences were fused to 260 bp of unknown sequence
(Figure 2). This new sequence failed to match any
known gene in the database including what was
known of the AF15q14 sequence at the time. Analysis
of the 400 bp chimeric cDNA amplified product
showed that an open reading frame was maintained
after the MLL sequence, thus potentially encoding
a novel fusion protein. The breakpoint in MLL results
in the loss of the final 8 nt from the 30 end of MLL
exon 8.
To confirm that this 400 bp amplified product was not
an artefact, we directly amplified the fusion from patient
material using the MLL exon 8 primers, and either
bottom primer B1 or B2 designed using the sequence
derived from the 400 bp product (Table 1, Figures 1 and
2). After nested PCR, we obtained products of the
expected sizes of 360 and 240 bp, respectively
(Figure 3a). The sequence of the PCR products matched
perfectly the sequence of the 400 bp product obtained
earlier, confirming that the 400 bp PCR product cloned
initially was derived from the chimeric cDNA and was
not a PCR artefact.
Table 1 Primer names and sequences
Primer name Primer sequence
MLL primers
MLL 5A 50AAG CCC GTC GAG GAA AAG AGT GAA GAA GGG AAT GTC TCG
MLL 5NP 50 GAT AAG CTT CCA GGA AGT CAA GCA AGC AGG 30
MLL 5UNP 50GCC TGA ATC CAA ACA GGC CAC CAC T 30
MLL F4 50 AAA AAA TTT AGG CTT GGC AAG GCG 30
MPFYVE primers
B1 50 GCC TGT GGG ACT GCC CTT CCG GGA GGA CC 30
B2 50 GGA GTC GTG CTA GGC GCT CAG CAA TCA TCT GG 3
NB1 50 GGT GTC TTC AGT GCT CTT GGC CTG CAC GTG C 30
NB2 50 CTT GTC GTG TCA GTC CCT GGC TCT GGG AAG 30
NG 32T 50 GAG GAA GTG CTT AAT AAA TGG AGG CTA TTG 30
NG 406B 50 GGA GAT CCC CCT CTC ACC CGC CCC TGC AGG 30
AF15 primers
AF15 6104B 50 TCT GTC GGG GTT TCT GTA TCA AGA TGT GGA 30
AF15 7421B 50 TGC TTG GTT GTT CCA ATG GTG GTC CAA GGG 30
AF15 6084B 50 CTC CCT TAT TGT TAT TCT CCC ATC TTG 30
AF15 7366B 50 CAT TCT TCA GGT AGT TGT TCT CCA GTG 30
AF15 T 50 GAC TGT TTT CTA TTC TAG TTG TAA TGA TGC 30
AF15 P2 50 TCT GAT GTG GTC ATA AGA TTT TGG AGC 30
AF15 NP2 50 TTC TTT TTC GGG TGT TGG TGC AGC TGC 30
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BLAST search of the EST database identified a set of
ESTs that were homologous to the novel sequence fused
to MLL. We sequenced two ESTs, T74136 (1.2 kb) and
AI191114 (2 kb), to identify the cDNA sequence of the
gene fused to MLL. The sequence comparison of the
two ESTs and the fusion cDNA revealed that they were
alternative splice products of the same gene (Figure 1b).
RT–PCR using RNA isolated from the cell line U937
and different primers within the EST sequence gave a
variety of alternatively spliced products including one
similar to the fusion transcript (data not shown).
EST AI 191114 contained almost the full-length
cDNA, but it is an incompletely processed transcript
containing intronic sequence at its 50 end. By comparing
the genomic sequence of the region available in the
database with our cDNA sequence (GenBank accession
number AF 445414), we predicted that MPFYVE
contains 12 exons and spans 10 kb of genomic DNA
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Figure 1 Genomic structure of MLL, MPFYVE and AF15 breakpoint regions. (a) Schematic representation of the MLL genomic
breakpoint region in the t(11;15). The long arrow indicates the chromosomal break. The locations of PCR primers are indicated as
horizontal arrows. Intron and exon sizes are indicated. (b) Genomic structure of MPFYVE. ‘X’ represents exons absent in the fusion
mRNA. ‘#’ represents the alternatively spliced exon between the two ESTs T74136 and AI191114. (c) Genomic structure of the
breakpoint region of AF15q14. The three known breaks in AF15q14 BP1 (Kuefer et al., this issue), BP2 (case studied here) and BP3
(Hayette et al., 2000) are indicated by long horizontal arrows. Primer 7421B is located in exon 27 (the last exon) and is not shown here.
(d) Orientation of the two BACs containing the MPFYVE and AF15q14 genes on chromosome 15
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(Figure 1b). The first two exons of 149 and 123 nt,
respectively, were not present in our longest EST clone
and were obtained by the Panorama program (available
through the University of Texas, Southwestern Medical
center internet site, http://www.atlas.swmed.edu) using
the genomic sequence from the database. The exons
predicted by gene scan and the rest of the exons
predicted by us, based on the sequence comparison,
matched perfectly.
MPFYVE and AF15q14 share only 15 bases of
homology at the 30 end of the 30 bp long AF15 NP2
primer. This 15-base identity with the AF15 NP2 primer
explains the amplification of the 400 bp RT–PCR
product obtained initially.
To evaluate the expression pattern of MPFYVE, we
probed a multiple tissue Northern blot with DNA
amplified from the 30 end of the EST T74136. A major
transcript of 1.35 kb was expressed in heart (H), skeletal
muscle (S), kidney (K) and liver (L) (Figure 4a). Minor
transcripts of 2.4 and 4.0 kb were also detected. A
Northern blot containing total RNA from two different
hematopoietic cell lines probed with the same probe
showed multiple transcripts ranging from 1.35 to 4.0 kb
(Figure 4b). The size of transcripts detected with the
MPFYVE probes is different from that of AF15q14 (8
and 9.5 kb), indicating that these are two different genes.
Probes from EST AI191114 and the RT–PCR products
obtained earlier gave the same expression pattern and
transcript sizes (data not shown).
As an independent confirmation of MLL–MPFYVE
fusion transcript expression, we used total RNA isolated
from patient material for RNase protection analysis.
The MLL–MPFYVE fusion fragment, originally iso-
lated by RT–PCR, was protected in the presence of
patient RNA, confirming the existence of the MLL–
MPFYE transcript in our patient (Figure 4d, lane 1). We
also confirmed expression of normal MPFYVE in this
same sample (Figure 4d, lane 1). The human b-actin
probe was used as a control for the quality of the patient
RNA (lane 4).
MPFYVE encodes a predicted protein of 48 kDa
(Figure 5a). The translation start codon is in the second
exon. The predicted amino-acid sequence showed no
striking homology to any of the known proteins in the
database but showed the presence of an FYVE domain
near its amino-terminus within exon 3. The FYVE
domain was detected using the NCBI’s Conserved
Domain (CD) database search. We named the new gene
that is fused to MLL as MLL partner containing a
FYVE domain (MPFYVE).
The predicted MLL–MPFYVE fusion protein con-
tains the AT-hooks and the repression domain of
MLL with P 1334 of MLL fused to P73 of MPFYVE
(Figure 5b). The predicted MLL–MPFYVE fusion
protein does not retain the FYVE domain of MPFYVE.
The MLL–MPFYVE fusion transcript isolated from
the patient material is an alternatively spliced form
of the MPFYVE gene and is capable of encoding a
1435 aa protein with a predicted molecular mass of
160 kDa.
To determine whether or not we could detect a fusion
ofMLL and AF15q14 in our patient, we performed RT–
PCR using the other downstream primers of AF15q14,
AF15 6104B and AF15 7421B and MLL exon 8 top
3         GCT TCC AGG AAG TCA AGC AAG CAG GTC TCC CAG CCA GCA CTG   47
0          A   S   R   K   S   S   K   Q   V   S   Q   P   A   L    14
48    GTC ATC CCG CCT CAG CCA CCT ACT ACA GGA CCG CCA AGA AAA GAA   92
15     V   I   P   P   Q   P   P   T   T   G   P   P   R   K   E    29
93    GTT CCC AAA ACC ACT CCT AGT GAG CCC AAG AAA AAG CAG CCT CCA   137
30     V   P   K   T   T   P   S   E   P   K   K   K   Q   P   P    44
138   CCA CCT CAG AAC TAT AAG AAG CGT GTG GCA GCC TTG GAA GCC AAG   182
45     P   P   Q   N   Y   K   K   R   V   A   A   L   E   A   K    59
183   CAA AAG CCC AGC ACT TCC CAG AGC CAG GGA CTG ACA CGA CAA GAC   227
60     Q   K   P   S   T   S   Q   S   Q   G   L   T   R   Q   D    74
228   CAG ATG ATT GCT GAG CGC CTA GCA CGA CTC CGC CAT GAT GCC TTT   272
75     Q   M   I   A   E   R   L   A   R   L   R   H   D   A   F    89
273   GAG CTT AAA GAG CAC CAA GAC ATC TGC CTA CTC TCC TCC ACG TGC   317
90     E   L   K   E   H   Q   D   I   C   L   L   S   S   T   C    104
318   AGG CCA AGA GCA CTG AAG ACA CCC TGG TCC TCC CGG AAG GGC AGT   362
105    R   P   R   A   L   K   T   P   W   S   S   R   K   G   S    119
363   CCC ACA GGC AGC TGC ACC  
120    P   T   G   S   C   T    
NG B2
NG B1
Figure 2 Sequence of the chimericMLL–MPFYVE cDNA. Sequence of the 400 bp chimeric cDNA cloned from the t(11;15) patient is
shown. The vertical arrow indicates the fusion junction between MLL and MPFYVE. Primers used in RT–PCR are indicated. MLL
and MPFYVE contain seven identical nucleotides at the breakpoint (underlined and bold)
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primers (Table 1 and Figure 1). Surprisingly, on the
second round of amplification, we obtained 500 and
1.8 kb products, respectively (Figure 3b). Cloning and
sequencing these products showed that the MLL exon 9
is fused to exon 12 of AF15q14. The size difference of
the RT–PCR products obtained with the two bottom
primers reflected the distance between the sites where
they annealed, approximately 1.3 kb. The chimeric
cDNA maintains the open reading frame, thus encoding
a putative MLL–AF15q14 fusion protein. Translation
of this chimeric cDNA sequence showed that the amino-
terminus of MLL up to K1362 is fused to the carboxy-
terminus of the AF15q14 starting at the amino acid I1819
(Figure 5c). The entire MLL–AF15q14 coding sequence
is 5658 bp and encodes a 1886 aa chimeric protein with a
predicted molecular mass of 208 kDa.
The genomic breakpoint of the t(11;15) from our
patient was cloned to identify the exact break in MLL
and AF15q14. Long-range PCR using genomic DNA
isolated from the bone marrow cells from our patient
and the MLL intron 9 top primer (MLL F4) and
AF15q14 bottom primer (AF15 6084B) amplified a
1.8 kb band that was sequenced to obtain the exact
sequence of the fusion junction between MLL and
AF15q14 (Figure 3c). Genomic PCR using MLL top
primers and MPFYVE bottom primers did not amplify
any fragment, indicating that there is only one genomic
breakpoint. The two different fusions we see here could
be due to alternative intragenic splicing between
AF15q14 and MPFYVE.
The sequence of the BACs containing AF15q14 and
MPFYVE is available in the database (AC022405 and
AC012476, respectively). The position of the two genes
within each BAC is known, as is the fact that these two
BACs overlap each other by 10 kb. We could therefore
estimate that the distance between the two genes is
Figure 3 RT–PCR showing the presence of both MLL–MPFYVE and MLL–AF15q14 chimeric transcripts in the t(11;15) patient
sample, and PCR of patient sample genomic breakpoint. (a) After nested PCR using MLL 5NP and the MPFYVE bottom primers,
either NB1 (lanes 1 and 2) or NB2 (lanes 3 and 4) products of 360 and 240 bp, respectively, were obtained. Either 1 : 30 (lanes 1 and 3)
or 1 : 300 (lanes 2 and 4) dilution of the first round PCR-amplified DNA was used as a template in the second round. M1 and M2
represent the 1 and 100 bp ladder (Gibco-BRL molecular weight standards), respectively. (b) RT–PCR of total RNA from the patient’s
bone marrow sample using MLL top primers and AF15q14 bottom primers. After nested PCR with MLL 5NP and either AF15q14
6084B or 7366B, 500 bp (lane 1) and 1.8 kb (lane 4) products were obtained, respectively. Lanes 2 and 3 represent no DNA template
negative controls. The marker is 1 kb plus ladder (Gibco-BRL) (lane M). (c) A 1.8 kb product was obtained (lane 3) usingMLL intron 6
top primer (MLL F4) and AF15q14 6084B bottom primer and genomic DNA isolated from the patient material. Marker (lane 1, 1 kb
ladder) and no template DNA PCR negative control (lane 2) are shown
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approximately 170 kb (Figure 1d). By fluorescence in
situ hybridization (FISH) using these BACs, we have
determined that AF15q14 is centromeric to MPFYVE
on chromosome 15 (Figure 6b).
The karyotype of this patient is complex and contains
a deleted chromosome 15 and three marker chromo-
somes. There is no normal chromosome 15. Our FISH
analysis with the AF15q14 BAC showed that it
hybridizes to three different chromosomes, the der(11),
der(15), which is the deleted chromosome 15 and a
marker chromosome; the probe is duplicated on the
marker chromosome. Thus, there appears to be a
duplication of AF15q14. The whole chromosome paint
15 (WCP15) confirmed the presence of chromosome 15
sequences on the marker chromosome to which the
AF15q14 BAC hybridizes (data not shown). Hybridiza-
tion of the AF15q14 probe to der(11), deleted chromo-
some 15 and the marker chromosome with chromosome
15 sequences, indicates that it contains the breakpoint of
t(11;15) (Figure 6a). The MLL probe also gave a split
signal between the der(11) and der(15) chromosomes,
confirming the involvement of MLL in this case; the
critical 50 MLL-30AF15q14 fusion is on the der(11)
chromosome. Different MPFYVE containing BACs did
Figure 4 Expression ofMPFYVE andMLL–MPFYVE RNA. (a) Multiple tissue Northern blot (Clontech Inc.) was probed with EST
T74136. A major transcript of 1.35 kb is expressed abundantly in heart, skeletal muscle, kidney and liver. Minor transcripts are detected
at 2.4 and 4.0 kb. (b) Northern blot containing total RNA from the two hematopoietic cell lines, HL60 and U937, indicates that there
are similar multiple transcripts encoded byMPFYVE ranging from 1.35 to 4.0 kb. (c) The same blot as in (a) was rehybridized with an
actin probe. (d) RNase protection assay. Patient RNA was hybridized with antisense RNA probe from either MLL–MPFYVE clone
(lane 1) or human b-actin (lane 4). The full lengthMLL–MPFYVE probe (506 nt) is indicated by (n). The fusionMLL–MPFYVE (416
nt) and normalMPFYVE (350 nt) protected messages are indicated by arrow and arrowhead, respectively (lane 1). Full-length (188 nt)
and protected (127 nt) human b-actin probe are indicated by (n) and arrow, respectively (lanes 3 and 4). Lanes 2 and 3 are undigested
probes
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not show a split signal; instead the entire MPFYVE
signal was translocated to the der(11), indicating
that MPFYVE is telomeric to AF15q14 (Figure 6b).
Moreover, the MPFYVE containing BACs only gave
one signal on the marker chromosome, indicating that
theMPFYVE gene is not duplicated. The importance of
the AF15q14 duplication is not currently understood.
Discussion
Cloning the chimeric cDNA and genomic breakpoint
junction formed by the t(11;15) from this patient reveals
a complex situation. We have identified two in-frame
fusions in which the 50 portion of MLL is fused to a
novel gene, MPFYVE, and a recently identified gene,
MVKADCPVPITDLPDSSGKLQYGCKNCGRAFCSGCLSFSAAVPRTGNTQQKVCKQCHE
VLTRGSSANASKWSPPQNYKKRVAALEAKQKPSTSQSQGLTRQDQMIAERLARLRQENKP
KLVPSQAEIEARLAALKDERQGSIPSTQEMEARLAALQGRVLPSQTPQPAHHTPDTRTQ
AQQTQDLLTQLAAEVAIDESWKGGGPAASLQNDLNQGGPGSTNSKRQANWSLEEEKS
RLLAEAALELREENTRQERILALAKRLAMLRGQDPERVTLQDYRLPDSDDDEDEETAI
QRVLQQLTEEASLDEASGFNIPAEQASRPWTQPRGAEPEAQDVDPRPEAEEEELPWCCI
CNEDATLRCAGCDGDLFCARCFREGHDAFELKEHQDICLLSSTCRPRALKTPWSSR
KGSPTGSGTHFWAQPQDVRWESLSGSTDDG*
MLL-MPFYVE
MLL                                            MPFYVE 
PKTTPSEPKKKQPPP1334 P73QNYKKRVAALEAKQK
MLL-AF15
MLL                                          AF15 
APRPSIPVKQKPKEK1362 I1819FDHHTEEDIDKSAN
a
b
c
Figure 5 (a) Predicted amino-acid sequence of MPFYVE, MLL–MPFYVE and MLL–AF15q14. The predicted molecular mass of
MPFYVE is 48 kDa. The MPFYVE protein contains an FYVE domain near its amino-terminus (underlined). The part of MPFYVE
present in MLL–MPFYVE is a product of an alternatively spliced mRNA where the first half (italicized) and second half (bold) are
joined together by splicing. (b, c) Predicted amino-acid sequence of the fusion junctions of MLL–MPFYVE (b) and MLL–AF15q14 (c)
are shown
Figure 6 FISH analysis of chromosomes from the t(11;15) patient sample. (a) FISH analysis using MLL and MPFYVE BACs as
probes. The MLL probe (red) showed three signals, on normal 11, der(11) (arrowhead) and der(15) (arrow). MPFYVE BACs showed
only two signals (green): marker chromosome which is a normal chromosome 15 and der(11) where the entire BAC was translocated,
telomeric toMLL. This indicates that the genomic break is 50 ofMPFYVE. (b) FISH analysis using AF15q14 andMPFYVE BACs as
probes. The AF15q14 BAC (red) showed three signals, on der(11) (arrowhead), der(15) (short arrow) and a marker chromosome, which
contains chromosome 15 sequences. The AF15q14 probe is duplicated on the marker chromosome as seen by the presence of two red
signals (long arrow). The MPFYVE probe (green) labels the der(11) and has a single signal on the marker chromosome
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AF15q14. The two putative fusion proteins retain the
AT-hooks, DNA methyltransferase homology and the
repression domains of MLL. In the MLL–MPFYVE
fusion, MLL exon 8 (minus 8 nt from the 30 end of the
exon) is fused to MPFYVE exon 4. Since the site of
fusion of MLL with MPFYVE is within an exon, it
could be a cryptic splice donor site/acceptor site
enabling the fusion to maintain its open reading frame.
Usage of cryptic splice donor and acceptor has been well
documented in MLL fusions (Caldas et al., 1998;
Divoky et al., 2000). Although canonical splice donor/
acceptor sequences are not present at the fusion
junction, we are confident that this is the real junction
sequence. We have independently PCR amplified this
junction using different primer pairs and sequenced the
PCR products both directly and after subcloning.
Further data supporting the existence of MLL–
MPFYVE fusion RNA come from the RNase protec-
tion assay (Figure 4d). Another interesting observation
of the fusion RNA is that the 7 nt at the junction
between MLL and MPFYVE are identical. The
importance of this 7 bp homology at the point of fusion
is unclear. Furthermore, the genomic break inMLL is in
intron 9, but theMLL–MPFYVE fusion did not contain
exon 9. This is likely owing to alternative splicing of
MLL exon 9, which has been previously described.
MPFYVE encodes a small protein containing 438
amino acids. The MPFYVE protein does not share
extensive homology to any previously identified proteins
but contains a highly conserved FYVE domain near its
amino-terminus. The FYVE domain is a zinc-finger
motif, which is conserved among many yeast, Caenor-
habditis elegans and mammalian proteins (Figure 7). It
was named ‘FYVE’ after four proteins (Fab1p, YOTB,
Vac1p and EEA1) containing this motif (Stenmark et al.
1996). The FYVE domain contains eight conserved
cysteines, which coordinate two Zn2+ ions (Schwabe and
Klug, 1994; Stenmark et al., 1996). In addition to the
cysteines, the R(R/K)HHCRxCG motif surrounding a
third and a fourth cysteine residue and an arginine at
position 68 are also highly conserved in the family
(Stenmark and Aasland, 1999). Several proteins, such as
Rabphilin 3A and Rim, lack the R(R/K)HHCRxCG
motif and the arginine at position 68 and are thus
characterized separately as FYVE-related domain con-
taining proteins. These proteins contain a conserved
Figure 7 FYVE domain alignment. (a) Alignment of the predicted FYVE finger domain of MPFYVE with closely related FYVE
domains present in other proteins. The alignment shown here is the result of the CD-Browser analysis (NCBI database). This figure is
modelled after the FYVE alignment published previously (Stenmark and Aasland, 1999). The FYVE domain of MPFYVE contains
only six cysteines and is missing the first two cysteines present in the consensus. R+HH is absent in MPFYVE, which makes it more
similar to the FYVE-related fingers. The absence of ‘R+HH’ is shown here by highlighting the existing residues ‘lqyg’ in bold. The
weakly conserved hydrophobic residue at position 67 is not conserved in MPFYVE (numbering specific to this figure). Arginine to
lysine at position 68 is a conservative change and therefore may not change the structure of the finger. # strongly conserved
hydrophobic;  strongly conserved acidic; + strongly conserved basic; % weakly conserved hydrophobic. (b) FYVE-related fingers.
The MPFYVE sequence is aligned with the known FYVE-related fingers described by Stenmark and Aasland (1999). Like other
FYVE-related fingers, MPFYVE lacks the R+HH motif, but still contains the glycine residue (bold) at a conserved position 39
(numbering specific to this figure) similar to the FYVE domain
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glycine at position 39. The FYVE domain of MPFYVE
resembles the FYVE-related domain as it lacks the R(R/
K)HHCRxCG motif and the arginine at position 68.
MPFYVE contains only six cysteines instead of eight
and hence represents a variant member of this family.
Most of the FYVE domain proteins are involved in
endosomal trafficking of proteins, but some are also
shown to be involved in other cellular processes, such as
signal transduction and cytoskeletal regulation (re-
viewed by Stenmark and Aasland, 1999). The FYVE
domain has been shown to bind to phosphotidyl-
inositol-3 phosphate (PtdIns(3)P) in the basic pocket
created by the R(R/K)HHCRxCG motif (Burd and
Emr, 1998; Gaullier et al., 1998; Patki et al., 1998;
Stenmark and Aasland, 1999). Proteins containing the
FYVE-related domain contain fewer basic residues in
this pocket area and only one of them is conserved
(position 39, Figure 7). Therefore, it is predicted that
these proteins bind to a less acidic or a neutral ligand.
Proteins containing the FYVE-related domain play roles
in regulated secretion. The MPFYVE protein contains
the variant form of the FYVE-related domain and
future functional tests will determine if it plays a role in
regulated secretion as do the other members of the family.
The second fusion we have identified is MLL–
AF15q14 in which the AF15q14 exon 12 is fused to
MLL exon 9. The breakpoint in AF15q14 reported here
is different from the two published breaks in AF15q14
(Hayette et al., 2000, Kuefer et al., this issue). The break
in AF15q14 in both cases is in exon 11. The MLL–
AF15q14 fusion protein described by Hayette et al.
contains only 85 amino acids of AF15q14, out of which
43 are encoded by exon 11. The remaining amino acids
are unique to the AF15q14 sequence described by
Hayette et al. and are not present in the sequence
reported by Kuefer et al. (this issue). The fusion
described here and by Kuefer et al. contains amino
acids encoded by exon 12 and further 30 of AF15q14.
Therefore, the AF15q14 amino-acid sequence of the
chimeric proteins studied here and by Kuefer et al. is
completely different from that present in the fusion
described by Hayette et al. The presence of two different
fusion transcripts in which MLL is fused to two
different genes is unique to the patient we studied. We
analysed RNA from the t(11;15) patient sample studied
by Kuefer et al. and could not amplify an MLL–
MPFYVE fusion from that patient material.
In the leukemia cells we studied here, the genomic
break is in intron 9 of MLL, and in intron 11 of
AF15q14. There is only one genomic break on chromo-
some 15. The presence of two different rearranged
transcripts of MLL has been observed in other cases
where MLL tandem duplication is present along with
the MLL–AF9 fusion transcript (Whitman et al., 2001).
The two different fusion transcripts we cloned here may
be the result of intragenic splicing. Although such
intragenic splicing has not been observed for MLL
fusions before, it has been reported in a t(3;21)
translocation (Nucifora et al., 1994). In the case of the
t(3;21), the AML1 gene on chromosome 21 is fused to
three genes EAP, MDS1 and EVI1, which are separated
from each other over a distance of approximately
450 kb. The two genes AF15 and MPFYVE are only
170 kb apart, with MPFYVE being telomeric to
AF15q14 (Figure 1d).
The presence of two different MLL fusion transcripts
raises an important question as to which of the two
transcripts (or both) are important for leukemia. Future
experiments using the two fusions in retroviral transduc-
tion of murine bone marrow progenitors will be able to
address this question.
Materials and methods
Patient material
Leukemic cells from an 11-year-old male with de novo AML-
M2 had a t(11;15)(q23;q14). Cytogenetic analysis at diagnosis
was unsuccessful because of inadequate material. The patient
relapsed after 1 year and cytogenetic analysis of the metaphase
chromosomes revealed a t(11;15)(q23;q14) as one of the
cytogenetic abnormalities. This patient material was obtained
with informed consent.
Cloning of the chimeric cDNA using 30 rapid amplification of
cDNA ends (RACE)
Total RNA from a frozen bone marrow sample collected at the
time of relapse was extracted using Tri Reagent (Molecular
Research Corp., Cincinnati, OH, USA) according to the
manufacturer’s guidelines. The first strand of cDNA was made
with 2 mg of total RNA using the Adapter primer following the
specifications outlined by the Gibco-BRL 30 RACE kit
(Gaithersburg, MD, USA). Polymerase chain reaction (PCR)
was used to amplify the putative fusion transcript using the
MLL exon 8 top primer MLL 5A (Table 1, Figure 1) and the
abridged universal amplification primer (AUAP) provided in
the kit. One-tenth of the first strand cDNA reaction was used
to synthesize the second strand in a standard PCR. The nested
PCR was carried out using 1/30th of the first round PCR-
amplified DNA,MLL 5NP and AF15 NP2 (Table 1, Figure 1).
The PCR products were resolved by electrophoresis on a 1%
TAE–agarose gel, purified using Gene Clean Extraction Kit
(BIO 101, Vista, CA, USA) and cloned in a TA cloning vector
(Invitrogen, Carlsbad, CA, USA). Sequencing reactions used
the ABI PRISM dye Terminator cycle sequencing Reaction
Ready kit (Perkin-Elmer, Foster City, CA, USA), following
the manufacturer’s specifications. Gel electrophoresis, data
collection and analyses were performed with an automated
sequencer (Model 377A, Applied Biosystems, Foster City, CA,
USA). Searches for sequence similarity were performed with
the GenBank nucleic acid databases using the BLAST
program (Adams et al., 1991).
Reverse transcription (RT)–PCR
One-tenth of the first strand cDNA synthesized for the 30
RACE protocol was used as a template to amplify the chimeric
cDNA product using MLL top primers and the gene-specific
bottom primers as follows:
Amplification of the MLL–MPFYVE fusion transcript A
different MLL exon 8 top primer (MLL 5UNP) and either
MPFYVE bottom primers B1 or B2 were used in the first
round PCR (Table 1, Figure 1). The nested PCR used 1/30th
and 1/300th of the amplified DNA from first round,MLL 5NP
with either NB1 or NB2. The cycling conditions used were
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2min at 941C, 30 cycles of 30 s at 941C, 2min at 581C, 2min at
721C and final extension at 721C for 7min.
Amplification of the MLL–AF15q14 fusion transcript MLL
5A and the AF15 6104B or AF15 7421B with an annealing
temperature of 601C were used in the first round of PCR
amplification (Table 1, Figure 1). One-thirtieth of the first
round PCR-amplified DNA with nested primers MLL 5NP
and the AF15 6084B or 7366B were used to amplify the RT–
PCR products (Table 1, Figure 1), respectively. The numbers
of the AF15 primers refer to the position in the nucleotide
(nt) sequence. The RT–PCR products were purified by gel
electrophoresis using 1.5% TAE–agarose, cloned into TA
cloning vector and sequenced as described above.
Long-range genomic PCR
Genomic DNA from the bone marrow sample of the patient
was isolated (Puregene DNA isolation kit, Gentra Systems,
Minneapolis, MN, USA), following the manufacturer’s
instructions. Long-range PCR (TaqPlus Long PCR system,
Stratagene, La Jolla, CA, USA) was performed using 300 ng
genomic DNA, 1 high-salt buffer, 200 nm of primers MLL
F4 and AF15 6084B, 200mm each of dATP, dCTP, dTTP,
dGTP and 5U of TaqPlus Long polymerase. The cycling
conditions used were 2min at 941C, 30 cycles of 30 s at 941C,
1min at 601C, 5min at 721C and final extension at 721C for
7min. The amplified fragment was purified and sequenced
using the MLL F4 primer.
Isolation of BACs containing AF15q14 and MPFYVE
A BAC library, containing human genomic DNA (Research
Genetics, Huntsville, AL, USA), was screened using the
manufacturer’s guidelines to isolate genomic clones containing
the AF15q14 and the MPFYVE genes. BAC 21B18 containing
the AF15q14 gene was isolated using primers AF15T and AF15
P2. BACs 164E2 and 147G20 containing MPFYVE were
isolated using primers NG 32T and NG 406B (Table 1,
Figure 1).
Purified BAC DNA was prepared using the Qiagen large-
scale plasmid kit. DNA isolated from these BACs and the
DNA from the BACs used for sequencing in the database
(534F12 and 2339L15) were used as probes in fluorescence in
situ hybridization (FISH) of patient chromosomes. A pre-
viously published probe for MLL from ONCOR was used.
Northern blot analysis
The human multiple tissue Northern blot was purchased from
Clontech Inc. (Palo Alto, CA, USA). The prehybridization
and hybridization were performed according to the manufac-
turer’s protocol using the expressed sequence tag (EST) clones
containing the MPFYVE sequences as probes.
RNase protection assay
The MLL–MPFYVE RT–PCR fragment cloned into PCR2.1
cloning vector (Invitrogen, Inc.) was used to make an antisense
RNA probe using T7 RNA polymerase. The probe was
synthesized by in vitro transcription, using the guidelines and
reagents of a Maxiscript kit from Ambion Inc. (Austin, TX,
USA) and biotin-labeled UTP (Roche). The RNase protection
assay was performed using the procedure described in the RPA
III kit (Ambion Inc.). The purified MLL–MPFYVE probe
(264 pg) was hybridized with 20ml of total RNA from the
patient sample, overnight at 42oC. Two separate controls with
the same amount of probe as test and 10mg of yeast RNA each
were set up. One of the yeast RNA tubes was treated with
RNase at the end of hybridization similar to the test sample,
and the other was not (intact probe). The yeast RNA sample
that was treated with RNase is a control for RNase digestion.
A human b-actin RNA probe (250 pg) was used to hybridize
with 10 ml of patient RNA as a control for quality of RNA.
After RNase digestion, the samples were run on a 5%
polyacrylamide/8m urea gel, transferred onto a nylon mem-
brane (Ambion, Inc.), using electroblotting and 1 TBE
buffer (BioRad, Inc., CA, USA) at 80mA for 1 h. The blot was
then processed using BrightStar BioDetect, a nonisotopic
detection kit from Ambion, Inc., following the manufacturer’s
guidelines.
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